Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Nivolumab in Mesothelioma, Malignant: NCT03502746 Clinical Landscape Report 2026
16 October 2026
NCT03502746 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LMB-100 in Malignant Mesothelioma of Peritoneum: NCT03436732 Clinical Landscape Report 2026
16 October 2026
NCT03436732 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Vamorolone in Muscular Dystrophy, Duchenne: NCT03439670 Clinical Landscape Report 2026
16 October 2026
NCT03439670 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Midazolam in Locally Advanced Malignant Solid Neoplasm: NCT03420742 Clinical Landscape Report 2026
16 October 2026
NCT03420742 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Etoposide in Refractory Soft Tissue Sarcoma: NCT03420963 Clinical Landscape Report 2026
16 October 2026
NCT03420963 clinical landscape for Refractory Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Avelumab in Microsatellite instability-high colorectal cancer: NCT03475953 Clinical Landscape Report 2026
16 October 2026
NCT03475953 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Pyridostigmine Bromide in Myasthenia Gravis: NCT03510546 Clinical Landscape Report 2026
16 October 2026
NCT03510546 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Suvodirsen in Muscular Dystrophy, Duchenne: NCT03508947 Clinical Landscape Report 2026
16 October 2026
NCT03508947 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-mesothelin thorium-227 labeled antibody chelator conjugate(Bayer) in Malignant Mesothelioma of Peritoneum: NCT03507452 Clinical Landscape Report 2026
16 October 2026
NCT03507452 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Vudalimab in Microsatellite instability-high colorectal cancer: NCT03517488 Clinical Landscape Report 2026
16 October 2026
NCT03517488 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Casimersen in Muscular Dystrophy, Duchenne: NCT03532542 Clinical Landscape Report 2026
16 October 2026
NCT03532542 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Mesothelioma, Malignant: NCT03531840 Clinical Landscape Report 2026
16 October 2026
NCT03531840 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.